Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix reported the outstanding shares and voting rights as of January 31, 2021. The company has 34,825,872 shares outstanding, with 36,003,389 total voting rights gross and 35,990,682 total voting rights net. This disclosure complies with the French Commercial Code and the regulations of the French Financial Markets Authority.

Nanobiotix operates in innovative oncology, with its lead product NBTXR3 authorized in Europe for soft tissue sarcoma. The company is listed on both Euronext Paris and NASDAQ under the ticker NBTX.

Positive

• Nanobiotix has over 34 million shares outstanding, indicating a solid shareholder base.
• Total voting rights net stands at approximately 36 million, suggesting significant shareholder engagement.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
January 31, 2021	34,825,872	36,003,389	35,990,682

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Switzerland, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at http://www.nanobiotix.comor follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005687/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

US – Porter Novelli

Dan Childs

+1 (781) 888-5106

dan.childs@porternovelli.com

Source: NANOBIOTIX

FAQ

What are the total number of voting rights for Nanobiotix as of January 31, 2021?

As of January 31, 2021, Nanobiotix has 36,003,389 total voting rights gross and 35,990,682 total voting rights net.

What is the significance of the voting rights announcement by Nanobiotix?

The announcement provides transparency regarding shareholder voting power and complies with regulations set by the French Financial Markets Authority.

Where is Nanobiotix listed?

Nanobiotix is listed on Euronext Paris and NASDAQ under the ticker NBTX.